Mechanisms in Chronic Myelogenous Leukemia
Under the leadership of the Editor-in-Chief, Dr Hagop Kantarjian, Mechanisms in Chronic Myelogenous
Leukemia (CML) provides medical professionals with highly interactive,
case-based online Learning Modules,
with content developed by an expert, multidisciplinary Editorial Committee of specialists
and certified through the American Academy of Continuing Medical Education (AACME) and the
Accreditation Council for Continuing Medical Education (ACCME).
All modules are further enhanced through state-of-the-art medical animations, with full audio narration, which elucidate key concepts in the treatment, management and application of therapeutic methods of CML.
This content on this Website is intended for medical oncologists, hematologists, stem cell transplant physicians, and other interested healthcare professionals who manage and treat chronic myelogenous leukemia in the hematology/oncology settings.
After successful completion of all Learning Modules, learners will be better able to:
- Describe the mechanisms of action and resistance to imatinib in CML
- Describe the criteria for response, suboptimal response, and failure of TKI therapy for CML
- Discuss novel techniques and therapies to monitor CML remission
- Discuss the status of emerging agents for patients with CML who fail or relapse after imatinib
- Review the criteria for diagnosing accelerated phase CML and discuss appropriate lines of treatment involving new TKI therapies
Click here to view the Learning Module Index